1. Scrip
  2. >>Business

Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022

Tebentafusp Granted Rare EU Accelerated Assessment

 
• By Andrew McConaghie

The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.

EMA
Rapid assessment US and EU reviews could see tebentafusp become the TCR receptor therapy approved in early 2022

Immunocore has filed its potential first-in-class T-cell receptor drug tebentafusp (IMCgp100) with regulators on both sides of the Atlantic, and the product could gain its first approval by February 2022.

The UK biotech, which has been around since 2008, is a pioneer in the field of T-cell receptor (TCR) therapies, an approach which has the potential to surpass antibody drugs and CAR-Ts in the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.